Second-gen tablets might increase dementia risk by a small-to-medium amount (there's almost certainly still a small degree of CNS activity, and we don't know what causes dementia in the first place), but researching it will be difficult. Dementia is hard to research because of how long it takes to develop, and it's poor coding within health data, and antihistamines are hard to research because they're not often prescribed and aren't available in the health data.
If it's a large effect, those factors wouldn't matter, but smaller risks are harder to detect and more sensitive to bias. If you want to minimise dementia risk, then reducing antihistamine use might be warranted, but you're probably better off addressing the risk factors we do know about: https://www.dementia.org.au/brain-health/risk-factors-develo...
Posting a claude chat is not actually helpful. The chat doesnt't even cite any sources.
I think this post is a decent summary, the answer is a soft maybe: https://www.health.harvard.edu/mind-and-mood/should-i-worry-...
Second-gen tablets might increase dementia risk by a small-to-medium amount (there's almost certainly still a small degree of CNS activity, and we don't know what causes dementia in the first place), but researching it will be difficult. Dementia is hard to research because of how long it takes to develop, and it's poor coding within health data, and antihistamines are hard to research because they're not often prescribed and aren't available in the health data.
If it's a large effect, those factors wouldn't matter, but smaller risks are harder to detect and more sensitive to bias. If you want to minimise dementia risk, then reducing antihistamine use might be warranted, but you're probably better off addressing the risk factors we do know about: https://www.dementia.org.au/brain-health/risk-factors-develo...